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Abstract
Background: Effective treatment strategies for chronic depression are urgently needed since it is not only a
common and particularly disabling disorder, but is also considered treatment resistant by most clinicians. There are
only a few studies on chronic depression indicating that traditional psycho- and pharmacological interventions are
not as effective as in acute, episodic depression. Current medications are no more effective than those introduced
50 years ago whereas the only psychotherapy developed specifically for the subgroup of chronic depression, the
Cognitive Behavioral Analysis System of Psychotherapy (CBASP), faired well in one large trial. However, CBASP has
never been directly compared to a non-specific control treatment.
Methods/Design: The present article describes the study protocol of a multisite parallel-group randomized
controlled trial in Germany. The purpose of the study is to estimate the efficacy of CBASP compared to supportive
psychotherapy in 268 non-medicated early-onset chronically depressed outpatients. The intervention includes 20
weeks of acute treatment with 24 individual sessions followed by 28 weeks of continuation treatment with another
8 sessions. Depressive symptoms are evaluated 20 weeks after randomisation by means of the 24-item Hamilton
Rating Scale of Depression (HRSD). Secondary endpoints are depressive symptoms after 12 and 48 weeks, and
remission after 12, 20, and 48 weeks. Primary outcome will be analysed using analysis of covariance (ANCOVA)
controlled for pre-treatment scores and site. Analyses of continuous secondary variables will be performed using
linear mixed models. For remission rates, chi-squared tests and logistic regression will be applied.
Discussion: The study evaluates the comparative effects of a disorder-specific psychotherapy and a well designed
non-specific psychological approach in the acute and continuation treatment phase in a large sample of early-
onset chronically depressed patients.
Trial registration: ClinicalTrials.gov (NCT00970437).
Background
Chronic depressions account for roughly up to a third of
all mood disorders [1,2]. In the literature, four subtypes
of chronic depression are distinguished: (1) dysthymia,
(2) chronic major depression, (3) recurrent major
depression with incomplete remission during episodes,
and (4) double depression [3]. Dysthymic disorder is
defined as a mild condition that persists for at least 2
years. Major depressive episode, chronic type, refers to a
more severe condition that meets full criteria for major
depression for a minimum of 2 subsequent years.
Patients who no longer meet full criteria for a major
depressive episode but continue to experience significant
symptoms for a total duration greater than 2 years are
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referred to as recurrent major depression with incom-
plete remission during episodes. The superimposition of
a major depressive episode on antecedent dysthymia is
termed as double depression [3]. The lifetime prevalence
rate for dysthymia in the US is estimated to be 6% and
the one-year prevalence rate around 3% [4]. The mean
length of the chronic course is approximately 17 to 30
years [5,2]. It is a particularly disabling disorder which is
associated with greater comorbidity, more significant
impairments in functioning, increased health care utiliza-
tion, and more frequent suicide attempts and hospitaliza-
tions than acute major depressive episodes [1]. It
therefore accounts for a considerable proportion of the
enormous economic burden associated with depression
[6]. In more than 70% of all cases, chronic depression
begins early in life [7], is mostly associated with early
interpersonal trauma and often persists life long. Early-
onset chronic depression results in an even more substan-
tial human capital loss compared with late-onset [8]. In
addition, the disorder has a more malignant course than
the late-onset group [9] and shows a high rate of relapse
after an initial response to medication treatment [10].
Although psychotherapy is commonly applied to
chronically depressed patients with early-onset there is
little data on the efficacy of psychological interventions
in this population. In a recent meta-analysis, Cuijpers et
al. [11] concluded that psychotherapy is effective in the
treatment of chronic depression and dysthymia but
probably less than pharmacotherapy. However, most of
the studies had methodological weaknesses such as the
very short courses of psychotherapy. Indications were
found that at least 18 treatment sessions are needed to
realize optimal effects of psychotherapy [11].
One large study (n = 681) [12] showed in a re-analysis
[13] that for the subgroup of chronically depressed
patients with an early childhood trauma, a psychothera-
peutic method specifically designed for chronic depres-
sion (Cognitive Behavioral Analysis System of
Psychotherapy/CBASP) was particularly effective. In
contrast, medication (nefazodone) alone had a weak
effect in this subgroup of patients as only 33% reached
remission (48% with CBASP). The combination of
CBASP and nefazodone resulted in a higher remission
rate (54%) than both monotherapies. Similarly, imipra-
mine but also more traditional psychotherapies (Inter-
personal Psychotherapy/IPT, and Cognitive Behavioral
Therapy) performed relatively poorly in early-onset
chronic Major Depression as shown by a reanalysis [14]
of the data of the NIMH-Collaborative study. In a pilot
study [15] with 30 chronically depressed outpatients
with early onset, statistically significant differences were
found between CBASP and IPT regarding remission
rates (57% in CBASP vs. 20% in IPT) and the reduction
of self-rated depressive symptoms in favor of CBASP.
The benefits of CBASP over IPT might have been due
to the extended course of therapy (22 sessions) and
sample characteristics (82% early traumatized subjects).
Based on these results, CBASP with and without med-
ication seems to be a highly promising method for early
onset chronic depression. Yet, CBASP was never com-
pared as a first-line treatment to a non-specific psycho-
logical intervention (active control). A control treatment
consisting of active but non-specific supportive psy-
chotherapy (SP) was used by Markowitz et al. [16] with
early-onset dysthymic patients as a comparator to IPT.
Supportive psychotherapy did perform as well as IPT
(both with low remission rates of 12% and 22%) sup-
porting the argument of Wampold et al. [17] that psy-
chological “placebos” - when properly designed and
structurally equivalent - are as effective as psychother-
apy in depressive disorders. This argument is supported
by a recent trial [18] where CBASP did not prove super-
ior to SP when applied as a short-term (12 sessions)
augmentation strategy in chronically depressed patients
showing partial or non-response to a medication algo-
rithm. In summary, the available data support the need
for more and larger trials, controlling for medication,
and including CBASP as a powerful intervention with a
more intensive (larger number of sessions) and a longer
course of treatment to unfold beneficial and lasting
effects in chronic depression.
Objectives
The purpose of the study is to estimate the efficacy of
CBASP compared to non-specific supportive psy-
chotherapy (SP) in 268 medication free, early onset
chronically depressed outpatients. The primary hypoth-
esis is that CBASP is more effective in reducing depres-
sive symptoms than SP. The secondary hypothesis




This investigator-initiated trial is registered as: “A com-
parison of the Cognitive Behavioural Analysis System of
Psychotherapy against supportive psychotherapy for
early onset chronic depression” at ClinicalTrials.gov
(NCT00970437). Figure 1 illustrates the study design of
this multisite, observer blind, prospective, parallel-group,
randomized, controlled trial with an active control and
two treatment phases (acute and continuation). A strati-
fied block randomization with randomly varying block
size is performed, stratified by trial center.
The intervention includes 20 weeks of acute treatment
with 24 individual sessions followed by 28 weeks of con-
tinuation treatment with another 8 sessions in each arm
of the trial.
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Oversight of research with human participants
The study is being conducted in compliance with the
protocol, Good Clinical Practice and the applicable
regulatory requirements. This research was approved
by the Institutional Review Board/Institutional Ethical
Committee (IRB/IEC) of the University of Freiburg
and the ongoing trial is under continued review by
the IRB/IEC. The local IRB/IECs of each participating
site were asked for confirmation prior to initiation.
Written informed consent is provided by all partici-
pants prior to clinical interview, randomization and
intervention.
Adverse Events and Serious Adverse Event (AE/SAE)
are reported to the project’s Data Safety and Monitoring
Board (DSMB) and SAEs to each IRB/IEC. Criteria for
discontinuation include for individuals: a) active suicid-
ality; b) the physical health of the patient is at risk
according to clinical judgment; c) occurrence of an AE/
SAE with therapeutic implications incompatible with the
study; d) newly occurring exclusion criteria, or e) the
informed consent is withdrawn. Parts of the trial or the
entire trial will be discontinued if: a) an investigator has
serious ethical concerns because of the performance at
one of the sites. b) severe safety concerns become
apparent to the DSMB.
In addition, the DSMB will conduct regular phone
conferences and visits at trial sites to ensure compliance
with ethical principles and the study protocol, as well as
to check data quality and accuracy.
Data collection sites
The patients are recruited and treated at eight clinical
sites in Germany:
1) Department of Clinical and Developmental Psychol-
ogy, University of Tuebingen, (Site Principal Investiga-
tor: Martin Hautzinger, PhD);
2) Department of Psychiatry, University of Heidelberg
(Site Principal Investigator: Matthias Backenstraß, PhD);
Figure 1 Trial design. CBASP: Cognitive Behavioral Analysis System of Psychotherapy. SP: Supportive Psychotherapy. Wk: week.
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3) Central Institute of Mental Health in Mannheim
(Site Principal Investigator: Josef Bailer, PhD);
4) Psychological Outpatient Clinic, University of Mar-
burg, (Site Principal Investigator: Katrin Wambach,
PhD);
5) Department of Psychiatry and Psychotherapy, Uni-
versity of Luebeck, Germany (Site Principal Investigator:
Philipp Klein, MD);
6) Department of Psychiatry; University Medical Cen-
ter Bonn (Site Principal Investigator: Dieter Schoepf,
MD);
7) Department of Psychosomatic Medicine and Psy-
chotherapy, University Medical Center Hamburg-Eppen-
dorf and Clinic Center Eilbek (Site Principal
Investigator: Bernd Löwe, MD)
8) Department of Psychiatry and Psychotherapy, Uni-
versity Medical Center Freiburg (Site Principal Investiga-
tor: Elisabeth Schramm, PhD).
Recruitment methods include project promotion
through reports in the media and by letters/announce-
ment to private practitioners. Most patients are expected
to be referred from practitioners. Patients have to be
unmedicated for at least 2 weeks prior to study entry. In
addition, the treating or a collaborating physician has to
attest that there is no contraindication for psychothera-
peutic treatment. When a review of medical history
necessitates doing so, a physical examination and appro-
priate laboratory tests are obtained to ensure that
patients are diagnostically eligible. Patient recruitment
started in March 2010.
All Site Principal Investigators will continue to meet
regularly by telephone (at least monthly or if necessary
more frequently) and at least twice annually in person
until study completion. Each research procedure is
described in detail in a procedure manual to facilitate
the implementation of the procedures in a consistent
manner across sites.
Inclusion and exclusion criteria
Key inclusion criteria are:
- a DSM-IV diagnosis of: 1) chronic Major Depressive
Disorder/MDD (at least 2 years duration), or 2) current
MDD superimposed on a pre-existing dysthymic disor-
der (so called “double-depression”), or 3) recurrent
MDD with incomplete remission between episodes.
Further inclusion criteria are:
- early onset (before the age of 21) according to DSM-
IV,
- age between 18 and 65, and
- a score of at least 20 on the 24-item Hamilton Rat-
ing Scale of Depression (HRSD).
Key exclusion criteria include:
- acute risk for suicide (as opposed to suicidal
thoughts) assessed according to clinical practice
guidelines; suicidal patients are eligible, as long as out-
patient treatment is deemed safe by the clinician,
- a history of psychotic symptoms, bipolar disorder, or
organic brain disorders,
- a primary diagnosis of another axis I disorder,
- antisocial, schizotypical, or borderline personality
disorder (SCID-II),
- severe cognitive impairment,
- a serious medical condition,
- absence of a response to a previous adequate trial of
CBASP and/or SP, and
- other ongoing psychotherapy or medication.
Interventions
CBASP as the experimental intervention follows a man-
ual [19,20] and is a highly structured approach based on
an interpersonal contemporary learning acquisition
model [21]. It is the only psychotherapy model devel-
oped exclusively for the treatment of chronic forms of
early-onset depression. The founder of the approach,
James McCullough, suggests that chronically depressed
patients suffer from a reduction of perceived functional-
ity, i.e. the ability to detect the effects of their own beha-
vior on other persons. This results in a pervasive degree
of social isolation, which worsens the depressive mood.
In addition, in chronic depressives early interpersonal
traumatization resulted in an inhibition of maturation in
childhood. CBASP focuses on the patient’s central
mechanisms of derailed affective and motivational regu-
lation by using the therapeutic relationship in a perso-
nal, disciplined way to shape dysfunctional interpersonal
behaviour. Further specific techniques (e.g. Interpersonal
Discrimination Exercise, Situation Analysis) are applied
to aid acquisition of perceived functionality in the
patient. In summary, CBASP integrates behavioral, cog-
nitive, and interpersonal strategies to help the patient
recognizing the consequences of their behavior and
interacting more effectively with others. Other goals of
CBASP include the transferal of social problem solving
strategies to the daily living, the interpersonal healing of
earlier trauma and to generate authentic empathy.
The alternative treatment, supportive psychotherapy, is
an active but less specific, manualized [22] control inter-
vention previously used in several comparative trials
[23]. SP - defined as non-interpersonal and non-cogni-
tive-behavioral therapy - resembles supportive clinical
management or client-centered counseling, and includes
psychoeducational elements. SP is also defined as a psy-
chotherapy wherein the therapist strives to create a sup-
portive relationship by emphasizing non-specific
therapeutic interactions and techniques that convey to
the patient the therapist’s interest, concern, and under-
standing. It utilizes the so-called common factors that
have been assumed to account for much of the effect of
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all tested psychotherapies. These common or non-speci-
fic factors include the facilitation of affect, helping the
patient to feel understood, to provide a framework for
understanding, empathy, a treatment ritual, success
experiences, hope and therapeutic optimism. It is
assumed that many clinicians in private practice proceed
in this unstructured manner. The explanatory mechan-
ism for treatment effect offered to the patient focuses
on the antidepressive effects of a supportive and under-
standing relationship, on the benefits of exploring and
expressing emotions, the patient-directed structure of
session and focus on personally relevant themes.
The number and duration of sessions as well as the
experience of the therapists is equivalent in both study
conditions. According to a meta-analysis of Baskin et al.
[24] structurally equivalent “placebos” produced negligi-
ble effects compared to active treatments [25]. But there
are also studies with depressed subjects which show sig-
nificant effects for supportive interventions [26,17]. Both
CBASP and SP are conducted with two weekly indivi-
dual sessions of 50 minutes each for the first 4 weeks
and 1 weekly session for the remaining 16 weeks in the
acute phase (=24 sessions, see Figure 1), followed by 8
continuation sessions over the next 28 weeks (2 sessions
in the first 4 weeks, and 1 session every 4 weeks there-
after). A 12-months naturalistic follow-up is planned for
a second study phase since sustainment of response is
particularly relevant given the chronic nature of the
disorder.
Medication/treatments during trial: In cases of severe
sleep problems, zolpidem is allowed for a maximum of
3 weeks. Central acting drugs are not allowed during
the study. Single dosages of non-steroid analgesics and
other non-centrally acting drugs for medical conditions
are permitted.
Description of risks
Psychotherapeutic treatment with CBASP as well as
with SP involves the chance of improvement of the
depressive symptomatology. Side effects of evidence-
based psychotherapies are fortunately rather rare [27].
Possible undesired „side-effects” may include transient
worsening of symptoms and transient risk of suicidality
at the beginning of therapy (due to breaking out of
avoidance behavior), but was rarely observed [28].
Therapist training and monitoring of adherence
CBASP and SP are implemented by two separate groups
of psychotherapists, both trained (in a 2-day training
workshop and at least 1 practice day) in one of the
methods and meeting the criteria for mastery of CBASP
or SP procedures as assessed by evaluation of their per-
formance during two videotaped pilot cases. All psy-
chotherapists have completed a 3-year psychotherapy
training program or are in an advanced stage of training.
All sessions will be videotaped and site-supervisors con-
tinue to review the videotapes regularly on a random
basis to assess psychotherapists’ adherence to the treat-
ment procedures using specific rating scales [19,29]. In
addition, a separate team of independent raters trained
to reliability will randomly evaluate several of the tapes
from early, middle, and late therapy phase of each treat-
ment for adherence and therapist competence. Site-
supervisors will be directly supervised by the trial-super-
visors (E. Schramm & M. Hautzinger) in terms of bi-




The 24-item-version of the HRSD has been implemen-
ted in the study by Keller et al. [12] and will therefore
provide internationally comparable study results. In
addition, the applied 16-item Quick Inventory of
Depressive Symptomatology, clinician-rated (QIDS-C16)
and the self-rated 30-item Inventory of Depressive
Symptomatology, Self-Report (IDS-SR) [30] have highly
acceptable psychometric properties [31].
Treatment expectation
In a modified version of the IDS-SR (E-IDS), patients
will be asked what they expect to answer in the IDS-SR
at the end of therapy.
Severity of anxiety
In order to identify anxiety as a possible predictor for
treatment outcome, symptoms of anxiety will be mea-
sured using the anxiety scale and the phobic anxiety
scale from the Brief Symptom Inventory (BSI). The BSI
is a validated self-report scale with strong test-retest and
internal consistency reliabilities. Factor analytic studies
of the internal structure of the scale have demonstrated
its construct validity [32]. Further, the GAD-7 [33] is
used. It is a valid and efficient tool with 7 items for
screening for generalized anxiety disorder.
Quality of life
The Medical Outcome Study 36-item Short Form
Health Survey (SF-36) [34] is an internationally
approved, generic instrument to assess Health-Related
Quality of Life (HRQoL). The 12-item Short Form Sur-
vey (SF-12), derived from the SF-36, has been demon-
strated to be reliable and valid in clinical and
population-based applications in the U.S. and other
countries [35-38]. A more disease-specific instrument is
the Quality of Life in Depression Scale (QLDS). This
34-item measure was developed to measure the impact
of depression symptoms and treatment on quality of life
[39]. The QLDS has evidence of reliability, construct
and content validity, and sensitivity to change in
depressed patients [40].
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Interpersonal problems
Interpersonal problems will be measured with the Ger-
man translation of the 64-item self-report Inventory of
Interpersonal Problems (IIP-64) [41]. Psychometric
research on the instrument in English-speaking commu-
nities as well as in German-speaking populations [41]
demonstrated the validity and the reliability (good inter-
nal consistency and test-retest reliability) of the IIP-64.
Social functioning
To measure global psychological, social, and occupa-
tional functioning, the widely utilized Global Assess-
ment of Functioning (GAF, Axis V in DSM-IV) scale
will be used. Another, more specific measurement is
the Social Adaptation Self-Evaluation Scale (SASS)
[42], particularly for self-assessment of social function-
ing by patients with depression. It contains 21 items
covering the different aspects of social interactions,
global social attitude, and self-perception. The SASS
has been validated and found to be simple to use and
sensitive to changes in the different areas of social
functioning [43].
Childhood trauma
At baseline, the Childhood Trauma Questionnaire
(CTQ) [44] will be completed. The CTQ is a 28-item
retrospective self-report questionnaire which determines
4 severity categories of emotional/physical/sexual abuse,
and emotional/physical neglect. “Early trauma” is
defined as one of these experiences before the age of 18
to a degree of at least “moderate to severe”. In addition,
the Early Trauma Inventory (ETI) [45], a 56-item semi-
structured interview is used. The ETI assesses also the
domain of general trauma (not assessed by CTQ). The
psychometric properties of both instruments have
shown to be favorable [46].
Evaluation by a relative
At the end of the therapy, a relative of the patient will
be asked to evaluate 14 items of depressive symptoms
before and after therapy.
Process analyses of therapies
After each session, the patients and therapists will fill
out the Helping Alliance questionnaire (HAQ) devel-
oped by Luborsky [47]. The instrument assesses two
types of alliance: patient’s experience of feeling helped
and supported by the therapist and patient’s experience
of working together with the therapist in a joint effort
in order to overcome the difficulties. The HAQ is corre-
lated with other well validated instruments [48], is also
highly correlated with treatment outcome [49] and
shows similar psychometric properties to other alliance
instruments [50].
Screening, socio-demographic, and medical data
The initial screening visit consists of a medical and psy-
chiatric history. Diagnoses will be derived using the
Structured Clinical Interview for DSM-IV (SCID-I and
II) [51,52] during the screening evaluation as well as
after 20 and 48 weeks of treatment. Sociodemographic
data include sex, age, nationality, marital status, educa-
tion, occupation, measure of household income, and
employment. Medical data refer to previous or present
diseases, outpatient and/or inpatient psychiatric and/or




Depressive symptoms 20 weeks after randomization




a) Depressive symptoms after 12 and 48 weeks mea-
sured by the HRSD;
b) Remission rates after 12, 20, and 48 weeks utilizing
the IDS-SR and defining remission a priori as a score of
13 or less for at least three consecutive weeks.
c) HRSD-remission rates (HRSD ≤ 8) and HRSD-
response rates (HRSD score by at least 50 percent from
baseline) will be calculated for the main measurement
time points.
d) Changes in QIDS-C16 (from baseline to week 12,
20, and 48);
e) Temporal changes in IDS-SR - Total sum score
between baseline assessment and follow-up assessments
(time course of 27 time points).
Measures taken to minimize/avoid bias
Randomization
The internet-based randomization will be conducted
according to a central computerized randomization
schedule, with a 1:1 treatment allocation ratio, stratified
by centre, in blocks of variable size, to guarantee con-
cealment. No-one can delete records from the randomi-
zation database, so that all randomizations have to be
accounted for. Audit log files detailing all activity on the
randomization system are available to the trial
coordinator.
Blinding
All clinical ratings will be completed by trained and
independent evaluators blinded to treatment assignment.
Each of the sites implements procedures to mask a
patient treatment assignment from the person who will
evaluate the results of the clinical ratings through the
following: 1) locating the rater at a separate physical
location, and 2) reminding the patients at each visit not
to mention anything that might reveal their treatment
condition to the independent evaluator. The baseline
and the HRSD interview at 20 weeks are videotaped and
will be evaluated by another rater.
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Control of therapy allegiance
Several recommendations for how to minimize the alle-
giance effect are considered: involving several investiga-
tors who represent a “mix of therapy allegiances”,
comparing interventions of the same length and dura-
tion, using blinded raters for process and outcome ana-
lyses, and conducting both interventions in all sites [53].
Control for overlapping treatments
The following measures are taken to prevent confound-
ing of treatment conditions through the overlap of treat-
ment methods:
Each therapist will conduct only one of the two treat-
ments. The therapists are obligated to adhere to the
therapeutic procedures and interventions described
within the manuals. Adherence to the treatment man-
uals will be continuously supervised by rating videotapes
of the sessions on a randomized basis using adherence
scales [19,29]. The validity of the therapist’s statements
will be checked through external assessment of the
video recordings. In the post-hoc-analysis it will be
checked if the expected differences regarding interven-
tion characteristics appear within the therapies.
Control for confounding factors
The influence of the trial site upon the effectiveness of
the respective treatment approaches will be investigated
as a separate factor. In addition, patients are asked not
to engage in off-study psychosocial (e.g., group therapy)
or psychiatric interventions (e.g. antidepressive medica-
tion) during the treatment period.
Statistical methods
Power calculation
The sample size calculation is based on the primary
hypothesis testing CPASP against SP with regard to
mean HRSD-scores at the end of the acute treatment
phase (null hypothesis: identical expected HRSD). We
considered a difference of five points on the HRSD
between mean post-treatment scores after 24 sessions of
the treated groups as clinically relevant. In similar stu-
dies, standard deviations of post-intervention HRSD-
scores of groups receiving CBASP, SP, or combinations
range from 5.4 to 10.4 points [12,16]. Assuming a com-
mon standard deviation of 10 points for two-group
comparisons yields a medium-sized effect of 0.5
(Cohen’s d). To detect this effect by a two-tailed t-test
with a power (1-b) of 0.95 and type I error probability
level of a = 0.05 for significance, 210 patients (105 per
group) are needed.
Assuming a drop-out rate of approximately 20% from
baseline to week 20, the maximum sample size is fixed
as 268 patients to be randomized. This is the number
needed for an appropriately powered per-protocol analy-
sis (only completers are analyzed). In the intention-to-
treat analysis, the higher number of patients is expected
to be compensated by a potential dilution of treatment
effects, so that the power will be approximately the
same.
Analyses
The final analyses will be performed in the intention to
treat (ITT) population, analyzing patients in treatment
groups to which they were randomized, and using the
last observation carried forward (LOCF) method in case
of missing outcome data at week 20. Because of the
chronic nature of the disorder, spontaneous remission is
unlikely to happen.
At main analysis, the null hypothesis of equal efficacy
will be tested (two-sided test) using analysis of covar-
iance (ANCOVA) controlled for pre-treatment scores
and site. Secondary analyses of the primary endpoint
will include a per-protocol approach, regression control-
ling for additional factors, and exploratory analyses of
treatment effect modifiers. To examine changes over
time, a mixed model approach to repeated measures
with 2 treatments by 4 measurement points will be
used: baseline, after 12 weeks, after 20 weeks (acute
intervention), and after 28 further weeks of continuation
treatment. Analyses of continuous secondary variables
will be performed using linear mixed models. For remis-
sion rates, chi-squared tests and logistic regression will
be used. The analysis of time to remission and time to
response will be analyzed using standard survival analy-
sis techniques. Level of significance will be set at a = .05
Discussion
Specific and effective treatment strategies for chronic
depression are urgently needed since the disorder is not
only recognized as highly prevalent and particularly
impairing, but is also considered “difficult-to-treat” or
even treatment resistant by most clinicians. There are
only a few studies on chronic depression indicating that
traditional interventions are less effective than in acute,
episodic depression. In addition, most of the studies had
methodological weaknesses, such as the very short
courses of psychotherapy. Usually, chronic depression
begins early in life, is often associated with early inter-
personal trauma, and the early onset course results in
an even more substantial human capital loss than the
late-onset. Furthermore, early onset depression shows a
weak response to medication and a high rate of relapse
after an initial response. Innovative antidepressant
approaches should aim at the regulation and mainte-
nance of mood stability over the long term rather than
at the acute resolution of symptoms. The only specific
and promising psychological intervention for chronic
depression, the CBASP, focuses on the patient’s central
mechanisms of derailed affective and motivational regu-
lation by using the therapeutic relationship in a perso-
nal, disciplined way to shape dysfunctional interpersonal
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behaviour. With the present multisite study, the efficacy
of CBASP is compared with a non-specific supportive
psychotherapy (a well-designed psychological control
treatment) in early onset chronically depressed patients.
The CBASP approach faired very well in one large trial
but has never been directly compared to a non-specific
control as first-line treatment. Another innovative aspect
of the study is the use of an extended course of psy-
chotherapy (32 sessions) since the very short courses of
psychotherapy in the study by Keller et al. [12] and in
other trials on chronic depression were probably too
short to provide an adequate test of psychotherapy.
Furthermore, it is planned to identify predictors of
response to CBASP vs. SP (e.g. early childhood trauma).
In process research, we will investigate which elements
of psychotherapy are most critical for an antidepressant
response to further improve the approach, if indicated.
Strengths and limitations
Even though the combination of psycho- and pharma-
cotherapy is the recommended gold standard for the
treatment of chronic depression in guidelines [54], to
test the relative efficacy of this very condition would
require a pharmacological placebo arm which would be
ethically questionable. The same is true for medication
alone. We consider medication alone also a relevant
treatment option since it is probably the most frequently
used strategy in clinical practice and maybe superior to
psychological interventions [11]. However, evidence
shows that it had a weak effect in the subgroup of early
onset chronic depression [13]. Furthermore, this type of
disorder shows a high rate of relapse after an initial
response to medication alone [7]. Given the long dura-
tion of the trial it would be unethical to keep non-
responsive patients on medication alone for 20 weeks.
In addition, the focus of the present trial is on the proof
of the CBASP-concept and its utility as a psychological
method and not on the comparable efficacy of CBASP
vs. medication. For the same reason and since it does
not reflect clinical practice, we do not use a CBASP plus
placebo condition. Thus, instead of trying to answer all
questions with one design we focus on a specific aim
addressing the efficacy of CBASP vs. supportive
psychotherapy.
In this trial the requirements for a low risk of bias
(sometimes also termed as “high methodological qual-
ity”) are met. Randomization, blinding of raters, control
of therapy allegiance and of overlapping treatments as
well as for confounding factors are described and war-
ranted by corresponding measures. The sample size is
large and the different orientation of the sites (dept. of
psychology, psychosomatic medicine, and psychiatry and
psychotherapy) allows the generalization of the results.
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